Levocetirizine

an update

Research output: Contribution to journalLiterature review

25 Citations (Scopus)

Abstract

Histamine plays a prominent and diverse role in the pathophysiology of allergic disease and therapeutic intervention is therefore typically focused on blocking the effects of this biogenic amine. A new antihistamine, levocetirizine, is the R-enantiomer of cetirizine dihydrochloride and like its parent compound undergoes minimal hepatic metabolism. Levocetirizine has pharmacodynamically and pharmacokinetically favourable characteristics, including high bioavailability, rapid onset of action, limited distribution and a low degree of metabolism. Clinical trials indicate that it is safe and effective for the treatment of allergic rhinitis and chronic urticaria with a minimal number of untoward effects. Furthermore, several recent studies have demonstrated that, in addition to its being a potent antihistamine, levocetirizine has several anti-inflammatory effects that are observed at clinically relevant concentrations that may enhance its therapeutic benefit.

Original languageEnglish
Pages (from-to)2711-2715
Number of pages5
JournalCurrent Medicinal Chemistry
Volume13
Issue number22
Publication statusPublished - 2006

Keywords

  • levocetirizine
  • antihistamine
  • allergy
  • anti-inflammatory
  • chronic idiopathic urticaria
  • persistent allergic rhinitis
  • healthy adult volunteers
  • placebo-controlled trial
  • quality-of-life
  • double-blind
  • histamine
  • asthma
  • desloratadine
  • cetirizine

Cite this

Levocetirizine : an update. / Walsh, Garry M.

In: Current Medicinal Chemistry, Vol. 13, No. 22, 2006, p. 2711-2715.

Research output: Contribution to journalLiterature review

Walsh, GM 2006, 'Levocetirizine: an update', Current Medicinal Chemistry, vol. 13, no. 22, pp. 2711-2715.
Walsh, Garry M. / Levocetirizine : an update. In: Current Medicinal Chemistry. 2006 ; Vol. 13, No. 22. pp. 2711-2715.
@article{1f4be6bf4c4c4bfa8f47b4a0eb94cb90,
title = "Levocetirizine: an update",
abstract = "Histamine plays a prominent and diverse role in the pathophysiology of allergic disease and therapeutic intervention is therefore typically focused on blocking the effects of this biogenic amine. A new antihistamine, levocetirizine, is the R-enantiomer of cetirizine dihydrochloride and like its parent compound undergoes minimal hepatic metabolism. Levocetirizine has pharmacodynamically and pharmacokinetically favourable characteristics, including high bioavailability, rapid onset of action, limited distribution and a low degree of metabolism. Clinical trials indicate that it is safe and effective for the treatment of allergic rhinitis and chronic urticaria with a minimal number of untoward effects. Furthermore, several recent studies have demonstrated that, in addition to its being a potent antihistamine, levocetirizine has several anti-inflammatory effects that are observed at clinically relevant concentrations that may enhance its therapeutic benefit.",
keywords = "levocetirizine, antihistamine, allergy, anti-inflammatory, chronic idiopathic urticaria, persistent allergic rhinitis, healthy adult volunteers, placebo-controlled trial, quality-of-life, double-blind, histamine, asthma, desloratadine, cetirizine",
author = "Walsh, {Garry M.}",
year = "2006",
language = "English",
volume = "13",
pages = "2711--2715",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "22",

}

TY - JOUR

T1 - Levocetirizine

T2 - an update

AU - Walsh, Garry M.

PY - 2006

Y1 - 2006

N2 - Histamine plays a prominent and diverse role in the pathophysiology of allergic disease and therapeutic intervention is therefore typically focused on blocking the effects of this biogenic amine. A new antihistamine, levocetirizine, is the R-enantiomer of cetirizine dihydrochloride and like its parent compound undergoes minimal hepatic metabolism. Levocetirizine has pharmacodynamically and pharmacokinetically favourable characteristics, including high bioavailability, rapid onset of action, limited distribution and a low degree of metabolism. Clinical trials indicate that it is safe and effective for the treatment of allergic rhinitis and chronic urticaria with a minimal number of untoward effects. Furthermore, several recent studies have demonstrated that, in addition to its being a potent antihistamine, levocetirizine has several anti-inflammatory effects that are observed at clinically relevant concentrations that may enhance its therapeutic benefit.

AB - Histamine plays a prominent and diverse role in the pathophysiology of allergic disease and therapeutic intervention is therefore typically focused on blocking the effects of this biogenic amine. A new antihistamine, levocetirizine, is the R-enantiomer of cetirizine dihydrochloride and like its parent compound undergoes minimal hepatic metabolism. Levocetirizine has pharmacodynamically and pharmacokinetically favourable characteristics, including high bioavailability, rapid onset of action, limited distribution and a low degree of metabolism. Clinical trials indicate that it is safe and effective for the treatment of allergic rhinitis and chronic urticaria with a minimal number of untoward effects. Furthermore, several recent studies have demonstrated that, in addition to its being a potent antihistamine, levocetirizine has several anti-inflammatory effects that are observed at clinically relevant concentrations that may enhance its therapeutic benefit.

KW - levocetirizine

KW - antihistamine

KW - allergy

KW - anti-inflammatory

KW - chronic idiopathic urticaria

KW - persistent allergic rhinitis

KW - healthy adult volunteers

KW - placebo-controlled trial

KW - quality-of-life

KW - double-blind

KW - histamine

KW - asthma

KW - desloratadine

KW - cetirizine

M3 - Literature review

VL - 13

SP - 2711

EP - 2715

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 22

ER -